The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

BACKGROUND: Mechanisms by which Smac mimetics (SMs) interact with proteasome inhibitors (e.g., bortezomib) are largely unknown, particularly in multiple myeloma (MM), a disease in which bortezomib represents a mainstay of therapy. METHODS: Interactions between the clinically relevant IAP (inhibitor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Hematol Oncol
Autors principals: Zhou, Liang, Zhang, Yu, Leng, Yun, Dai, Yun, Kmieciak, Maciej, Kramer, Lora, Sharma, Kanika, Wang, Yan, Craun, William, Grant, Steven
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6407248/
https://ncbi.nlm.nih.gov/pubmed/30845975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0713-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars